Biomarker-Based Predictive Models for Prognosis in Amyotrophic Lateral Sclerosis
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Although median survival in amyotrophic lateral sclerosis (ALS) is 2 to 4 years, survival ranges from months to decades, creating prognostic uncertainty. Strategies to predict prognosis would benefit clinical management and outcomes assessments of clinical trials. OBJECTIVE: To identify biomarkers in plasma and cerebrospinal fluid (CSF) of patients with ALS that can predict prognosis. DESIGN, PARTICIPANTS, AND SETTING: We conducted a retrospective study of plasma (n = 29) and CSF (n = 33) biomarkers identified in samples collected between March 16, 2005, and August 22, 2007, from patients with ALS at an academic tertiary care center. Participants included patients who were undergoing diagnostic evaluation in the neurology outpatient clinic and were eventually identified as having definite, probable, laboratory-supported probable, or possible ALS as defined by revised El-Escorial criteria. All were white and none had a family history of ALS. Clinical information extended from initial presentation to death. Genotyping for hemochromatosis (HFE) gene status was performed. Multiplex and immunoassay analysis of plasma and CSF was used to measure levels of 35 biomarkers. Statistical modeling was used to identify biomarker panels that could predict total disease duration. MAIN OUTCOMES AND MEASURES: Total disease duration, defined as the time from symptom onset to death, was the main outcome. The hypothesis being tested was formulated after data collection. RESULTS: Multivariable models for total disease duration using biomarkers from plasma, CSF, and plasma and CSF combined incorporated 7, 6, and 6 biomarkers to achieve goodness-of-fit R2 values of 0.769, 0.617, and 0.962, respectively. After classification into prognostic categories, actual and predicted values achieved moderate to good agreement, with Cohen κ values of 0.526, 0.515, and 0.930 for plasma, CSF, and plasma and CSF combined models, respectively. Inflammatory biomarkers, including select interleukins, growth factors such as granulocyte colony-stimulating factor, and l-ferritin, had predictive value. CONCLUSIONS AND RELEVANCE: This study provides proof-of-concept for a novel multivariable modeling strategy to predict ALS prognosis. These results support unbiased biomarker discovery efforts in larger patient cohorts with detailed longitudinal follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00210-5 · Cited by 3,307
Sabat, R., Grütz, G., Warszawska, K., Kirsch, S., Witte, E., Wolk, K., & Geginat, J. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.09.002 · Cited by 977
Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis
Ferraiuolo, L., Kirby, J., Grierson, A. J., Sendtner, M., & Shaw, P. J. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.152 · Cited by 615
Rosengren, L. E., Karlsson, J., Karlsson, J., Persson, L. I., & Wikkelsø, C. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67052013.x · Cited by 499
Axonal damage markers in cerebrospinal fluid are increased in ALS
Brettschneider, J., Petzold, A., Süßmuth, S. D., Ludolph, A. C., & Tumani, H. (2006) · Neurology · doi:10.1212/01.wnl.0000203120.85850.54 · Cited by 261
Cited by
Kell, D. B., & Pretorius, E. (2014) · Metallomics · doi:10.1039/c3mt00347g · Cited by 667
Gravel, M., Béland, L.-C., Soucy, G., Abdelhamid, E., Rahimian, R., Gravel, C., & Kriz, J. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.0854-15.2016 · Cited by 117
Biomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
Gille, B., De Schaepdryver, M., Dedeene, L., Goossens, J., Claeys, K. G., Van Den Bosch, L., Tournoy, J., Van Damme, P., & Poesen, K. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319586 · Cited by 88
Pagliardini, V., Pagliardini, S., Corrado, L., Lucenti, A., Panigati, L., Bersano, E., Servo, S., Cantello, R., D'Alfonso, S., & Mazzini, L. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.12.016 · Cited by 42
Metadata
- Authors
- Su, X. W., Simmons, Z., Mitchell, R. M., Kong, L., Stephens, H. E., & Connor, J. R.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2013-10-21
- Volume
- 70
- Issue
- 12
- Pages
- 1505-11
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2011875602
- Cited by
- 59
- References
- 5
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarker-Based Predictive Models for Prognosis in Amyotrophic Lateral Sclerosis. https://app.cochat.ai/papers/10.1001/jamaneurol.2013.4646
- The paper
- Su, X. W., Simmons, Z., Mitchell, R. M., Kong, L., Stephens, H. E., & Connor, J. R. (2013). Biomarker-Based Predictive Models for Prognosis in Amyotrophic Lateral Sclerosis. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2013.4646
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.